---
company: VEEVA SYSTEMS INC
ticker: VEEV
form: 8-K
filed: 2026-06-03
accession: 0001393052-26-000022
source: https://www.sec.gov/Archives/edgar/data/1393052/000139305226000022/
---

# Veeva Systems (VEEV) earnings release, June 3, 2026

Veeva Systems Inc (VEEV) · Form 8-K, Item 2.02 · Filed 2026-06-03 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1393052/000139305226000022/)

Veeva Announces Fiscal 2027 First Quarter Results

Total Revenues of $882.9M, up 16% Year Over Year

Subscription Revenues of $730.2M, up 15% Year Over Year

PLEASANTON, CA — June 3, 2026 — Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its first quarter ended April 30, 2026.

"Our rapid progress with Veeva AI sets the foundation as we enter the next chapter of our industry cloud," said CEO Peter Gassner. "We are moving from an industry-specific application company to an industry-specific application and AI agent company. This is a major transformation for Veeva and the industry that will help our customers bring the right medicines to patients faster."

Fiscal 2027 First Quarter Results:

• Revenues

: Total revenues for the first quarter were $882.9 million, up from $759.0 million one year ago, an increase of 16% year over year. Subscription revenues for the first quarter were $730.2 million, up from $634.8 million one year ago, an increase of 15% year over year.

• Operating Income and Non-GAAP Operating Income

:

(1)

First quarter operating income was $273.1 million, compared to $233.7 million one year ago, an increase of 17% year over year. Non-GAAP operating income for the first quarter was $395.4 million, compared to $349.9 million one year ago, an increase of 13% year over year.

• Net Income and Non-GAAP Net Income

:

(1)

First quarter net income was $260.9 million, compared to $228.2 million one year ago, an increase of 14% year over year. Non-GAAP net income for the first quarter was $371.1 million, compared to $327.8 million one year ago, an increase of 13% year over year.

• Net Income per Share and Non-GAAP Net Income per Share

:

(1)

For the first quarter, fully diluted net income per share was $1.57, compared to $1.37 one year ago, while non-GAAP fully diluted net income per share was $2.24, compared to $1.97 one year ago.

“Our first quarter results exceeded guidance on all metrics, reflecting another quarter of broad-based growth and profitability,” said CFO Brian Van Wagener. “We’re pleased with the raised fiscal 2027 guidance and energized by the large and growing opportunity ahead.”

Recent Highlights:

• Advancing Industry AI with Rapid Progress Across Veeva AI – Veeva significantly advanced its industry AI strategy this quarter. Ostro, acquired in March, is delivering compliant, conversational AI for more than 50 brands. Vault AI is on track to expand to all Vault applications in August. Veeva Falcon, the new platform delivering agentic labor for clinical, regulatory, and safety, is planned for early adopter release in November.

• Leading the Industry with Agentic Commercial – At Commercial Summit in May, Veeva shared its vision for Agentic Commercial, leveraging AI to help biopharmas bring the right medicines to more patients. With capabilities like the Agentic Call Report in Vault CRM and Ostro’s conversational AI on brand websites, biopharmas can now generate and act on Commercial Evidence. In Vault CRM, the industry’s fastest path to Agentic CRM success, Veeva added 27 new Vault CRM customers in the quarter and now has more than 150 customers live.

• Bringing Agentic Labor to Veeva Development Cloud – Veeva expanded its leadership with multiple enterprise biopharma wins across clinical, regulatory, and safety. Additionally, Veeva showcased its AI strategy at the recent European R&D and Quality Summit in Copenhagen, generating strong customer interest in Vault AI and Veeva Falcon to drive productivity and speed in drug development.

Financial Outlook:

Veeva is providing guidance for its fiscal second quarter ending July 31, 2026 as follows:

• Total revenues between $902 and $905 million.

• Non-GAAP operating income between $392 and $395 million.

(2)

• Non-GAAP fully diluted net income per share between $2.21 and $2.22.

(2)

Veeva is providing updated guidance for its fiscal year ending January 31, 2027 as follows:

• Total revenues between $3,635 and $3,645 million.

• Non-GAAP operating income of about $1,610 million.

(2)

• Non-GAAP fully diluted net income per share of approximately $9.05.

(2)

Conference Call Information

Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva's investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, June 3, 2026, and a replay of the call will be available on Veeva's investor relations website.

___________

(1)

This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled

“

Non-GAAP Financial Measures” and the tables entitled

“

Reconciliation of GAAP to Non-GAAP Financial Measures” below for details.

(2)

Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the second fiscal quarter ending July 31, 2026 or the fiscal year ending January 31, 2027 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva Systems

Veeva delivers the industry cloud for life sciences with cloud software, AI, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com... (truncated) upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking Statements

This release contains forward-looking statements regarding Veeva’s expected future performance and, in particular, includes quotes from management and guidance, provided as of June 3, 2026, about Veeva’s expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance.

There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, availability, security, or privacy of our products, competitive factors, customer decisions and priorities, developments that impact the life sciences industry (including regulatory, funding, or policy changes), general macroeconomic and geopolitical events (including changes in trade policy or practices, inflationary pressures, currency exchange fluctuations, changes in interest rates, and geopolitical conflicts), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled “Summary of Risk Factors” on pages 13 and 14 in our filing on Form 10-K for the period ended

January 31, 2026 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-K and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

###

## Financial statements

### Income Statement (Three months ended April 30, — (Unaudited))

| | Three months ended April 30, – 2026 | 2025 |
|---|---:|---:|
| Revenues: | Subscription(3) | 730,175 | 634,768 |
| Revenues: | Professional services and other(4) | 152,773 | 124,275 |
| Revenues: | Total revenues | 882,948 | 759,043 |
| Cost of revenues(5): | Cost of subscription | 99,103 | 78,346 |
| Cost of revenues(5): | Cost of professional services and other | 121,821 | 95,478 |
| Cost of revenues(5): | Total cost of revenues | 220,924 | 173,824 |
| Cost of revenues(5): | Gross profit | 662,024 | 585,219 |
| Operating expenses(5): | Research and development | 208,323 | 184,033 |
| Operating expenses(5): | Sales and marketing | 111,117 | 98,628 |
| Operating expenses(5): | General and administrative | 69,472 | 68,826 |
| Operating expenses(5): | Total operating expenses | 388,912 | 351,487 |
| Operating expenses(5): | Operating income | 273,112 | 233,732 |
| Operating expenses(5): | Other income, net | 74,418 | 65,089 |
| Operating expenses(5): | Income before income taxes | 347,530 | 298,821 |
| Operating expenses(5): | Income tax provision | 86,594 | 70,631 |
| Operating expenses(5): | Net income | 260,936 | 228,190 |
| Net income per share: | Basic | 1.6 | 1.4 |
| Net income per share: | Diluted | 1.57 | 1.37 |
| Weighted-average shares used to compute net income per share: | Basic | 163,345 | 162,749 |
| Weighted-average shares used to compute net income per share: | Diluted | 165,989 | 166,229 |
| Other comprehensive income: | Net change in unrealized (loss) gain on available-for-sale investments | -27,451 | 17,367 |
| Other comprehensive income: | Net change in cumulative foreign currency translation loss | -501 | -38 |
| Other comprehensive income: | Comprehensive income | 232,984 | 245,519 |
| (3) Includes subscription revenues from the following product areas: | Veeva Commercial Solutions | 337,866 | 305,411 |
| (3) Includes subscription revenues from the following product areas: | Veeva R&D and Quality Solutions | 392,309 | 329,357 |
| (3) Includes subscription revenues from the following product areas: | Total subscription | 730,175 | 634,768 |
| (4) Includes professional services and other revenues from the following product areas: | Veeva Commercial Solutions | 57,573 | 46,567 |
| (4) Includes professional services and other revenues from the following product areas: | Veeva R&D and Quality Solutions | 95,200 | 77,708 |
| (4) Includes professional services and other revenues from the following product areas: | Total professional services and other | 152,773 | 124,275 |
| Cost of revenues: | Cost of subscription | 1,761 | 1,715 |
| Cost of revenues: | Cost of professional services and other | 14,151 | 12,769 |
| Cost of revenues: | Research and development | 51,563 | 47,949 |
| Cost of revenues: | Sales and marketing | 24,594 | 22,321 |
| Cost of revenues: | General and administrative | 27,190 | 27,456 |
| Cost of revenues: | Total stock-based compensation | 119,259 | 112,210 |

### Income Statement (Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-G — The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:)

| | 2026 | Three months ended April 30, – 2026 | 2026 | 2025 |
|---|---:|---:|---:|---:|
| Net cash provided by operating activities on a GAAP basis |  | 1,127,116 |  | 877,158 |
| Excess tax deficiency (benefit) from employee stock plans |  | 4,092 |  | -2,579 |
| Net cash provided by operating activities on a non-GAAP basis |  | 1,131,208 |  | 874,579 |
| Net cash used in investing activities on a GAAP basis |  | -388,711 |  | -52,107 |
| Net cash (used in) provided by financing activities on a GAAP basis |  | -262,526 |  | 20,380 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Cost of subscription revenues on a GAAP basis |  |  | 99,103 | 78,346 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Stock-based compensation expense |  |  | -1,761 | -1,715 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Amortization of purchased intangibles | -674 |  |  | -1,012 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Cost of subscription revenues on a non-GAAP basis |  |  | 96,668 | 75,619 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Gross margin on subscription revenues on a GAAP basis | 86.4 |  |  | 87.7 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Stock-based compensation expense | 0.2 |  |  | 0.3 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Amortization of purchased intangibles | 0.2 |  |  | 0.1 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Gross margin on subscription revenues on a non-GAAP basis | 86.8 |  |  | 88.1 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Cost of professional services and other revenues on a GAAP basis |  |  | 121,821 | 95,478 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Stock-based compensation expense |  |  | -14,151 | -12,769 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Amortization of purchased intangibles |  |  |  | -134 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Cost of professional services and other revenues on a non-GAAP basis |  |  | 107,670 | 82,575 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Gross margin on professional services and other revenues on a GAAP basis | 20.3 |  |  | 23.2 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Stock-based compensation expense | 9.2 |  |  | 10.3 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Amortization of purchased intangibles |  |  |  | 0.1 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Gross margin on professional services and other revenues on a non-GAAP basis | 29.5 |  |  | 33.6 |
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Gross profit on a GAAP basis |  |  | 662,024 | 585,219 |

### Income Statement (Three months ended April 30, — (Unaudited))

| | Three months ended April 30, – 2026 | 2025 |
|---|---:|---:|
| Sales and marketing expense on a GAAP basis | 111,117 | 98,628 |
| Stock-based compensation expense | -24,594 | -22,321 |
| Amortization of purchased intangibles | -2,331 | -2,795 |
| Sales and marketing expense on a non-GAAP basis | 84,192 | 73,512 |
| General and administrative expense on a GAAP basis | 69,472 | 68,826 |
| Stock-based compensation expense | -27,190 | -27,456 |
| General and administrative expense on a non-GAAP basis | 42,282 | 41,370 |
| Operating expense on a GAAP basis | 388,912 | 351,487 |
| Stock-based compensation expense | -103,347 | -97,726 |
| Amortization of purchased intangibles | -2,331 | -2,795 |
| Operating expense on a non-GAAP basis | 283,234 | 250,966 |
| Operating income on a GAAP basis | 273,112 | 233,732 |
| Stock-based compensation expense | 119,259 | 112,210 |
| Amortization of purchased intangibles | 3,005 | 3,941 |
| Operating income on a non-GAAP basis | 395,376 | 349,883 |
| Operating margin on a GAAP basis | 30.9% | 30.8% |
| Stock-based compensation expense | 13.5 | 14.8 |
| Amortization of purchased intangibles | 0.4 | 0.5 |
| Operating margin on a non-GAAP basis | 44.8% | 46.1% |
| Net income on a GAAP basis | 260,936 | 228,190 |
| Stock-based compensation expense | 119,259 | 112,210 |
| Amortization of purchased intangibles | 3,005 | 3,941 |
| Income tax effect on non-GAAP adjustments(6) | -12,063 | -16,513 |
| Net income on a non-GAAP basis | 371,137 | 327,828 |
| Diluted net income per share on a GAAP basis | 1.57 | 1.37 |
| Stock-based compensation expense | 0.72 | 0.68 |
| Amortization of purchased intangibles | 0.02 | 0.02 |
| Income tax effect on non-GAAP adjustments(6) | -0.07 | -0.1 |
| Diluted net income per share on a non-GAAP basis | 2.24 | 1.97 |

### Balance Sheet ((Unaudited))

| | April 30, 2026 | January 31, 2026 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 1,896,580 | 1,421,233 |
| Current assets: | Short-term investments | 5,416,139 | 5,139,581 |
| Current assets: | Accounts receivable, net | 568,020 | 1,259,737 |
| Current assets: | Unbilled accounts receivable | 59,752 | 50,609 |
| Current assets: | Prepaid expenses and other current assets | 122,770 | 126,470 |
| Current assets: | Total current assets | 8,063,261 | 7,997,630 |
| Current assets: | Property and equipment, net | 73,484 | 70,261 |
| Current assets: | Deferred costs, net | 28,686 | 29,961 |
| Current assets: | Lease right-of-use assets | 82,060 | 75,626 |
| Current assets: | Goodwill | 488,161 | 439,877 |
| Current assets: | Intangible assets, net | 55,508 | 30,314 |
| Current assets: | Deferred income taxes | 272,665 | 273,417 |
| Current assets: | Other long-term assets | 65,733 | 62,257 |
| Current assets: | Total assets | 9,129,558 | 8,979,343 |
| Current liabilities: | Accounts payable | 40,657 | 37,644 |
| Current liabilities: | Accrued compensation and benefits | 52,572 | 45,857 |
| Current liabilities: | Accrued expenses and other current liabilities | 50,974 | 45,885 |
| Current liabilities: | Income tax payable | 67,897 | 6,698 |
| Current liabilities: | Deferred revenue | 1,476,539 | 1,488,819 |
| Current liabilities: | Lease liabilities | 13,131 | 12,153 |
| Current liabilities: | Total current liabilities | 1,701,770 | 1,637,056 |
| Current liabilities: | Deferred income taxes | 1,148 | 558 |
| Current liabilities: | Long-term lease liabilities | 89,936 | 83,706 |
| Current liabilities: | Other long-term liabilities | 32,350 | 43,271 |
| Current liabilities: | Total liabilities | 1,825,204 | 1,764,591 |
| Stockholders’ equity: | Common stock | 2 | 2 |
| Stockholders’ equity: | Additional paid-in capital | 2,699,707 | 2,843,089 |
| Stockholders’ equity: | Accumulated other comprehensive (loss) income | -19,792 | 8,160 |
| Stockholders’ equity: | Retained earnings | 4,624,437 | 4,363,501 |
| Stockholders’ equity: | Total stockholders’ equity | 7,304,354 | 7,214,752 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 9,129,558 | 8,979,343 |

### Cash Flow (Three months ended April 30, — (Unaudited))

| | Three months ended April 30, – 2026 | 2025 |
|---|---:|---:|
| Cash flows from operating activities | Net income | 260,936 | 228,190 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 11,587 | 9,822 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Reduction of lease right-of-use assets | 3,279 | 3,265 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Accretion of discount on short-term investments | -1,788 | -2,509 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Stock-based compensation | 119,259 | 112,210 |
